Antioxidized LDL Antibodies Are Associated With Different Metabolic Pathways in Patients With Atherosclerotic Plaque and Type 2 Diabetes
Por:
Bernal-Lopez, MR, Garrido-Sanchez, L, Gomez-Carrillo, V, Gallego-Perales, JL, Llorente-Cortes, V, Calleja, F, Gomez-Huelgas, R, Badimon, L, Tinahones, FJ
Publicada:
1 abr 2013
Resumen:
OBJECTIVE-Oxidized lipoproteins and antioxidized LDL antibodies (antioxLDL abs) have been detected in human plasma and atherosclerotic lesions. The principle aim of this study was to analyze the possible relationship between IgG and IgM antioxLDL abs and factors involved in different metabolic pathways (inflammation, lipid metabolism, apoptosis, and cell cycle arrest profile) in the occluded popliteal artery (OPA) compared with the femoral vein (FV).
RESEARCH DESIGN AND METHODS-Fifteen patients with advanced atherosclerosis and type 2 diabetes undergoing lower limb amputation participated in this study. Each patient had OPA and FV biopsy specimens and peripheral arterial occlusive disease. By real-time PCR, gene expression was analyzed from the OPA and FV specimens, and antioxLDL ab levels were measured by specific enzyme-linked immunosorbent assay.
RESULTS-The OPA and FV showed a positive correlation between only IgM antioxLDL ab levels and the expression of genes involved in different metabolic pathways, including inflammation (TFPI), apoptosis (BAX, caspase 3, AKT1), plaque disruption (MMP2 and MMP10), lipid metabolism (SCARB1, PPARg), and cell turnover (CDKN1A), and genes for transcription and growth factors (NFkB and VEGFA, respectively).
CONCLUSIONS-The results show that gene expression in the metabolic pathways (apoptosis, lipid metabolism, and inflammation) in the OPA and FV are directly related to the levels of IgM antioxLDL abs. Diabetes Care 36:1006-1011, 2013
Filiaciones:
Bernal-Lopez, MR:
Hosp Clin Virgen de la Victoria, Biomed Res Lab, Endocrinol & Nutr Dept, Malaga, Spain
Inst Salud Carlos III, CIBER Fisiopatol Obesidad & Nutr CB 06 003, Madrid, Spain
Garrido-Sanchez, L:
Univ Rovira & Virgili, Endocrinol & Diabet Unit, Joan Univ Hosp 23, IISPV, Tarragona, Spain
CIBERDEM, Barcelona, Spain
Gomez-Carrillo, V:
Hosp Reg Univ Carlos Haya, Dept Internal Med, Malaga, Spain
Gallego-Perales, JL:
Hosp Reg Univ Carlos Haya, Dept Gen Surg, Malaga, Spain
Llorente-Cortes, V:
Hosp Santa Creu & Sant Pau, CSIC ICCC, Cardiovasc Res Ctr, Barcelona, Spain
Calleja, F:
Hosp Reg Univ Carlos Haya, Dept Cardiovasc Surg, Malaga, Spain
Gomez-Huelgas, R:
Inst Salud Carlos III, CIBER Fisiopatol Obesidad & Nutr CB 06 003, Madrid, Spain
Hosp Reg Univ Carlos Haya, Dept Internal Med, Malaga, Spain
Badimon, L:
Inst Salud Carlos III, CIBER Fisiopatol Obesidad & Nutr CB 06 003, Madrid, Spain
Tinahones, FJ:
Hosp Clin Virgen de la Victoria, Biomed Res Lab, Endocrinol & Nutr Dept, Malaga, Spain
Inst Salud Carlos III, CIBER Fisiopatol Obesidad & Nutr CB 06 003, Madrid, Spain
Green Published, Hybrid Gold
|